EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials

Angelica Rivas, Newaz Shubidito Ahmed, Yuhong Yuan, Anila Qasim, David B O'Gorman, Brian G Feagan, Vipul Jairath iD, Albert J Bredenoord, Evan S Dellon, Christopher Ma iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18382 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Angelica Rivas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High placebo responses have limited drug development in eosinophilic oesophagitis. The optimal configuration of trial outcomes is uncertain.

Aims

To inform more efficient future trial designs, to characterise clinical, endoscopic and histologic placebo responses in eosinophilic oesophagitis randomised controlled trials (RCTs).

Methods

We updated a Cochrane systematic review and meta‐analysis, searching multiple databases to January 1, 2024, to identify placebo‐controlled RCTs evaluating medical therapies for patients with eosinophilic oesophagitis. The primary outcome was the pooled proportion of study‐defined clinical, endoscopic and histologic responders and remitters randomised to placebo, using an intention‐to‐treat approach and random‐effects model. Sources of heterogeneity were explored using meta‐regression.

Results

We included 25 RCTs. The pooled proportion of clinical response was 41.0% [95% CI: 29.7%–52.8%] with substantial heterogeneity ( I 2 = 74.9%). On meta‐regression, older age and a higher probability of being randomised to placebo reduced the likelihood of clinical response to placebo. The pooled proportion of histologic remission defined as a peak eosinophil count [PEC] ≤ 6 eosinophils per high power field [HPF] or ≤ 1 eosinophil/HPF was 4.3% [95% CI: 2.6%–6.2%] ( I 2 = 23.6%) and 1.3% [95% CI: 0.5%–2.5%] ( I 2 = 0%), respectively. The standardised mean difference in the Eosinophilic Oesophagitis Endoscopic Reference Score to placebo was −0.25 [95% CI: −0.41, −0.10].

Conclusions

Over 40% of patients in eosinophilic oesophagitis trials respond clinically to placebo, and this is associated with trial design factors such as randomisation ratio and trial population. Objective endoscopic and histologic measures are associated with very low placebo responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisRandomized Controlled Trials as TopicHumansPlacebo EffectTreatment OutcomePlacebosEosinophils

Substanzen

Placebos

Autor:innen und Institutionen

  • Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gastroenterology, London Health Science Centre, London, Ontario, Canada.
  • Department of Medicine, Western University, London, Ontario, Canada.
  • Alimentiv Inc, London, Ontario, Canada.
  • Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

ORCID-Profile: Vipul Jairath, Christopher Ma

Zitieren

APA

Rivas, A., Ahmed, N. S., Yuan, Y., Qasim, A., O'Gorman, D. B., Feagan, B. G., Jairath, V., Bredenoord, A. J., Dellon, E. S., & Ma, C. (2025). Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18382

Vancouver

Rivas A, Ahmed NS, Yuan Y, Qasim A, O'Gorman DB, Feagan BG, et al. Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18382

BibTeX
@article{Rivas2025,
  author = {Rivas, Angelica and Ahmed, Newaz Shubidito and Yuan, Yuhong and Qasim, Anila and O'Gorman, David B and Feagan, Brian G and Jairath, Vipul and Bredenoord, Albert J and Dellon, Evan S and Ma, Christopher},
  title = {Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18382}
}
Kostenlos starten →